Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bioengineering
Sirtris Pharmaceuticals and Sirtuin Academic Thought Leaders Publish Review on the Therapeutic Potential of Sirtuins for Diseases of Aging
August 31st, 2007
Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging, announced that Sirtris, together with leading sirtuin researchers David A Sinclair, Ph.D. and Leonard P. Guarente, Ph.D., published a review in the MIT Tech Review entitled "Developing Drugs to Treat Diseases of Aging." The review highlights the discovery of sirtuins, a novel class of enzymes, and their role in the aging process. Additionally, the article discusses the drug development path of SIRT1 activators as potential treatments for a range of diseases of aging including metabolic disorders such as Type 2...
Source: Drug Week (2007-08-31)
|
